Canagliflozin treatment of Hispanic and non-Hispanic patients with type 2 diabetes in a US managed care setting

AbstractBackground:Hispanic/Latino (H/L) ethnicity is associated with higher prevalence of type 2 diabetes mellitus (T2DM) and more complications and comorbidities. Few studies of antihyperglycemic agents (AHAs) have compared H/L with non-H/L patients. Randomized controlled trials and observational studies have shown canagliflozin (CANA) is effective at lowering hemoglobin A1C (A1C).Objective:To describe characteristics and compare glycemic control between H/L and non-H/L patients with T2DM filling their first prescription for CANA.Methods:This retrospective cohort study examined healthcare claims for diabetic patients who filled ≥1 prescription for CANA between 1 April 2013 and 31 October 2013. We captured available demographic data; ethnicity was imputed as previously published. Clinical data included the Diabetes Complications Severity Index (DCSI), A1C values, and claims for any AHA, with 6 months of follow-up.Results:Our sample included 438 (11.4%) H/L individuals and 3408 (88.6%) non-H/L individuals...